ZZ Biotech, LLC has announced that it has commenced dosing healthy volunteers in a Phase 1 clinical study with 3K3A-APC, a recombinant variant of human activated protein C (APC), being developed for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results